Treatment of early diabetic nephropathy with Valsartan

Objective: To evaluate and observe the effect of angiotensinⅡⅠ type receptor antagonists(AT1Ra) Valsartan on the early diabetic nephropathy with microalbuminuria. Methods: 64 cases of type 2 diabetes mellitus(DM ) [24h urine albumine excretion rate (UAER)20～200 μg/min] were divided into four groups at random; one was normal control group(n=16), the others were given Valsartan 80 mg qd(n=16) Valsartan 160 mg qd (n=16),Enaplapril 20 mg qd (n=16), and placebo(n=16) respectively without changing the previous management of DM. After 12 weeks of the treatment the changes of mean arterial pressure(MAP),UAER,HbA1c,Ccr were observed. Results: No change of the above indices was observed in the control group. In the other three groups the MAP and 24 h UAER, changed significantly(P0 05). The decrease in micro albumin excretion rate was not related to the change of blood pressure。Conclusion: AT1Ra Valsartan is effective in reducing microalbumin excretion in the early diabetic nephropathy and is well tolerated in the patients.